Filing identity and reporting period
Important identity discrepancy: The supplied filing is ESGEN Acquisition Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2023, not a Zeo Energy Corp. filing. ESGEN was a shell company seeking a business combination; it had not commenced operating activities or generated operating revenue. The report was signed May 15, 2023.
Financial results and condition
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Operating revenue | None | None |
| Operating costs | $1.513 million | $0.873 million |
| Net income (loss) | $(1.446) million | $5.881 million |
| Trust-account interest income | $0.941 million | $0.018 million |
| Change in warrant fair value | $(0.874) million expense | $6.735 million gain |
| Operating cash flow | $0.724 million provided | $0.238 million used |
Q1 2023 operating costs were primarily legal and professional fees ($1.369 million). No operating margin is meaningful because ESGEN had no operating revenue. The filing reports no conventional operating debt; current obligations included $3.064 million accounts payable and accrued expenses, $0.249 million due to related parties, and a $0.171 million related-party promissory note. It also reported $9.660 million in deferred underwriting fees at March 31, subsequently waived by the underwriters in April.
At March 31, cash outside the trust was $50,471, versus $614,767 at December 31, 2022. Trust-account securities were $30.919 million, down from $285.507 million, principally following redemptions. Total liabilities were $14.815 million; redeemable Class A shares were $30.919 million; shareholders’ deficit was $14.727 million.
Material changes and transactions
- In January 2023, shareholders approved an extension mechanism for the business-combination deadline. Holders redeemed 24,703,445 Class A shares for approximately $255.876 million, about $10.35 per share. The remaining redeemable public shares numbered 2,896,555 at quarter-end.
- On April 19, 2023, after quarter-end, ESGEN signed a business-combination agreement with Sunergy Renewables, LLC. The transaction was expected to close in Q4 2023, subject to shareholder approval and other conditions; it was not completed as of this filing.
- The proposed transaction included a $10 million sponsor PIPE investment, with additional financing to be pursued. Closing required aggregate transaction proceeds of at least $20 million, among other conditions.
- On April 5, ESGEN issued the sponsor an unsecured, non-interest-bearing note of up to $1.5 million. Approximately $1.385 million was outstanding as of May 11, repayable only from funds outside the trust and due at the business-combination closing.
- The underwriters waived their deferred commission in April 2023.
Outlook, risks, and controls
Management stated that outside-trust cash and borrowing capacity were insufficient to fund operations through the earlier of a business-combination closing or one year from the filing. The company had until May 22, 2023, subject to further extensions, to complete a combination; failure to complete or extend would trigger liquidation. Management concluded that these conditions raised substantial doubt about ESGEN’s ability to continue as a going concern.
Disclosure controls and procedures were reported ineffective because a previously identified material weakness remained. The weakness involved an inadequate control environment and insufficient accounting and internal-control expertise, including controls over earnings-per-share calculations and cash-flow classification. Management described remediation plans but gave no assurance they would be effective. The filing also cites economic and geopolitical uncertainty, transaction execution and financing risks, possible further redemptions, and potentially significant transaction costs. No legal proceedings were reported.
Key facts investors should verify
- Confirm the intended issuer: this filing is for ESGEN Acquisition Corporation, not Zeo Energy Corp.
- Verify the status and final terms of the proposed Sunergy transaction, including approvals, closing conditions, financing, and any subsequent amendments or termination.
- Check extensions, redemptions, trust-account balance, and cash available outside the trust after March 31, 2023.
- Review subsequent sponsor-note borrowings and repayment terms, and confirm the effect of the underwriters’ fee waiver.
- Assess remediation of the material weakness and any later changes to management’s going-concern assessment.
- Note that ESGEN checked “No” to having filed all required Exchange Act reports during the preceding 12 months.